Suhag Patel1, Raxitkumar Jinjuvadia, Ravi Patel, Suthat Liangpunsakul. 1. *Department of Medicine, Division of Gastroenterology, Detroit Medical Center/Wayne State University †Department of Medicine, Division of Gastroenterology, Henry Ford Hospital ‡Detroit Medical Center, Detroit, MI §Department of Medicine, Indiana University Medical Center and Roudebush Veterans Administration Medical Center, Division of Gastroenterology and Hepatology, Indianapolis, IN.
Abstract
BACKGROUND: The role of insulin resistance (IR) on fibrosis progression in hepatitis C virus (HCV) patients has not been systematically evaluated. Therefore, this systemic review aimed to summarize the available epidemiologic evidence to evaluate the strength of association between IR and advanced liver fibrosis in these patients. METHODS: We performed a systemic literature search in PubMed, OvidSP, and MEDLINE from January 1990 to April 2015 without language restriction using the following search terms: insulin resistance, liver fibrosis, cirrhosis, diabetes mellitus, and chronic hepatitis C. Publication bias was assessed using the Begg and Egger tests and with a visual inspection of funnel plot. All analyses were performed using Comprehensive Meta-Analysis, version 2 software. RESULTS: A total of 3659 participants with HCV infection from 14 studies were included in the analysis. After adjusting for publication bias, the relative risk (RR) for significant hepatic fibrosis among HCV subjects with IR was 1.63 [95% confidence interval (CI), 1.34-2.01]. Subgroup analysis by genotypes showed RR of 2.16 (95% CI, 1.52-3.06) for genotype 1; however, the association was no longer significant when we analyzed the data for HCV genotype 3; RR=1.40 (95% CI, 0.8-2.45). CONCLUSION: Our study showed significant association between IR and significant hepatic fibrosis in patients with HCV genotype 1 infection.
BACKGROUND: The role of insulin resistance (IR) on fibrosis progression in hepatitis C virus (HCV) patients has not been systematically evaluated. Therefore, this systemic review aimed to summarize the available epidemiologic evidence to evaluate the strength of association between IR and advanced liver fibrosis in these patients. METHODS: We performed a systemic literature search in PubMed, OvidSP, and MEDLINE from January 1990 to April 2015 without language restriction using the following search terms: insulin resistance, liver fibrosis, cirrhosis, diabetes mellitus, and chronic hepatitis C. Publication bias was assessed using the Begg and Egger tests and with a visual inspection of funnel plot. All analyses were performed using Comprehensive Meta-Analysis, version 2 software. RESULTS: A total of 3659 participants with HCV infection from 14 studies were included in the analysis. After adjusting for publication bias, the relative risk (RR) for significant hepatic fibrosis among HCV subjects with IR was 1.63 [95% confidence interval (CI), 1.34-2.01]. Subgroup analysis by genotypes showed RR of 2.16 (95% CI, 1.52-3.06) for genotype 1; however, the association was no longer significant when we analyzed the data for HCV genotype 3; RR=1.40 (95% CI, 0.8-2.45). CONCLUSION: Our study showed significant association between IR and significant hepatic fibrosis in patients with HCV genotype 1 infection.
Authors: K Ishak; A Baptista; L Bianchi; F Callea; J De Groote; F Gudat; H Denk; V Desmet; G Korb; R N MacSween Journal: J Hepatol Date: 1995-06 Impact factor: 25.083
Authors: P Halfon; G Pénaranda; F Carrat; P Bedossa; M Bourlière; D Ouzan; C Renou; A Tran; E Rosenthal; C Wartelle; P Delasalle; P Cacoub Journal: Aliment Pharmacol Ther Date: 2009-03-09 Impact factor: 8.171
Authors: M Yoneda; S Saito; T Ikeda; K Fujita; H Mawatari; H Kirikoshi; M Inamori; Y Nozaki; T Akiyama; H Takahashi; Y Abe; K Kubota; T Iwasaki; Y Terauchi; S Togo; A Nakajima Journal: J Viral Hepat Date: 2007-09 Impact factor: 3.728
Authors: Diego García-Compeán; Emanuela Orsi; Ramesh Kumar; Felix Gundling; Tsutomu Nishida; Jesús Zacarías Villarreal-Pérez; Ángel N Del Cueto-Aguilera; José A González-González; Giuseppe Pugliese Journal: World J Gastroenterol Date: 2022-02-28 Impact factor: 5.742